NCT06762925 Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment Status NOT_YET_RECRUITING Phase N/A
NCT06682793 A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression Status RECRUITING Phase PHASE1/PHASE2
NCT06673329 Brodalumab in the Treatment of Immune-Related Adverse Events Status RECRUITING Phase PHASE1
NCT06648902 Safety and Preliminary Efficacy of Meldonium in Patients with Metastatic Renal Cell Carcinoma and Treatment-associated Fatigue Status COMPLETED Phase PHASE1/PHASE2
NCT06585878 A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma Status NOT_YET_RECRUITING Phase NA
NCT06582849 Enhanced Assistance During Radiotherapy for Unmet Essential Needs Status COMPLETED Phase NA
NCT06577961 Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT06536439 Planning Operative Strategy Using a Digital Renal Artery Clamping Tool Status RECRUITING Phase NA
NCT06532422 Study of Post-operative Complications After Laparoscopic Outpatient Nephrectomy Status RECRUITING Phase N/A
NCT06531629 Risk-based Screen and Prognostic Analysis for Second Primary Malignancies in Kidney Cancer Patients Status COMPLETED Phase N/A
NCT06369519 Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma Status COMPLETED Phase N/A
NCT06362369 A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy Status RECRUITING Phase PHASE1/PHASE2
NCT06264479 Prospective Evaluation of AI R&D Tool for Patient Stratification: a Trial for Renal Immuno-oncology Model Experimental Evaluation 2 Status TERMINATED Phase N/A
NCT06214000 Primary Care-Based Follow-up of Cancer Survivors of the Prostate and Kidney Status COMPLETED Phase N/A
NCT06211790 Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma Status RECRUITING Phase PHASE2